Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures
retigabine, ezogabine
VRX-RET-E22-301
NCT00232596
Seizures
Phase 3
 
March 2015

Powered by ideaPoint, Inc.